Protection against Tick-Borne Encephalitis with a New Vaccine Formulation Free of Protein-Derived Stabilizers | Zendy

Olaf Zent | Zendy; Renald Hennig | Zendy; Angelika Banzhoff | Zendy; Bröker Michael | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Protection against Tick-Borne Encephalitis with a New Vaccine Formulation Free of Protein-Derived Stabilizers

Author(s) -

Olaf Zent,

Renald Hennig,

Angelika Banzhoff,

Bröker Michael

Publication year - 2006

Publication title -

journal of travel medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.985

H-Index - 59

eISSN - 1708-8305

pISSN - 1195-1982

DOI - 10.2310/7060.2005.12205

Subject(s) - medicine , pharmacovigilance , clinical trial , seroconversion , immunogenicity , tick borne encephalitis , vaccination , postmarketing surveillance , adverse effect , immunology , encephalitis , antibody , virus

Vaccination against tick-borne encephalitis (TBE) has been successfully employed for many years in TBE-endemic countries. Post-marketing experience gained from widespread use, however, prompted the development of improved TBE vaccines, the most modern versions of which do not contain the commonly used protein-derived stabilizers (human albumin or polygeline) of former vaccines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research